Product Data Sheet

Diclazuril-d₄

Cat. No.: HY-B0357S
CAS No.: 1632495-80-7
Molecular Formula: $C_{17}H_5D_4Cl_3N_4O_2$

Molecular Weight: 411.66

Target: Parasite; Antibiotic; Isotope-Labeled Compounds

Pathway: Anti-infection; Others

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 25 mg/mL (60.73 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|------------|------------|
| | 1 mM | 2.4292 mL | 12.1459 mL | 24.2919 mL |
| | 5 mM | 0.4858 mL | 2.4292 mL | 4.8584 mL |
| | 10 mM | 0.2429 mL | 1.2146 mL | 2.4292 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Diclazuril-d₄ is deuterium labeled Diclazuril. Diclazuril (R-64433), a benzeneacetonitrile derivative, is a potent and orally active anticoccidial agent. Diclazuril can be used for the research of certain infectious and parasitic diseases, including coccidiosis, acute toxoplasmosis, equine protozoal pyoencephalitis (EPM) et.al[1][2].

IC₅₀ & Target Coccidia

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

In Vitro

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.



Page 2 of 2 www.MedChemExpress.com